Malvern, PA – According to filings with the U.S. Securities and Exchange Commission, Xylocor Therapeutics is raising $4,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Albert Gianchetti played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Xylocor Therapeutics

XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. Our lead product candidate, XC001, is in clinical development for patients with refractory angina for which there are no treatment options. XyloCor also has a secondary product, XC002, in discovery stage, for patients with cardiac tissue damage from heart attacks.

To learn more about Xylocor Therapeutics, visit http://xylocor.com/

Contact:
Albert Gianchetti, Chief Executive Officer
888-290-0081
al.gianchetti@xylocor.com
https://www.linkedin.com/in/al-gianchetti-555539/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved